• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Facing Shortage, Novo Nordisk Halts All Marketing for Wegovy

Article

Advertising pause aims to prevent stimulating further demand, company says.

Injections for body beauty and weight loss. Tablets, syringe and yellow measuring tape. Image Credit: Adobe Stock Images/adragan

Image Credit: Adobe Stock Images/adragan

Novo Nordisk, a Danish pharmaceutical company, is pausing all advertising efforts for Wegovy, a drug prescribed for obesity, in an effort to curb growing demand. The organization believes that the popularity of this medication is due to its promotion as a weight-loss panacea by influencers on social media, mainly TikTok.

In addition to slowing down advertisements, there have been production issues. In April, Novo said it would increase the supply of Wegovy after initial contract manufacturing difficulties.

According to the company, promotional efforts aimed at healthcare professionals are also being assessed for potential adjustments.

Reference: Shortage of Wegovy Leads Novo Nordisk to Pause All Advertisements. May 23, 2023/Health News

Related Videos
Related Content